Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more

Recent & Breaking News (NDAQ:ATOS)

Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA's Expanded Access Pathway

GlobeNewswire April 8, 2021

Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update

GlobeNewswire March 31, 2021

Physician-Scientist Steven Quay Provides Open Letter Response to WHO Report: Five Undisputed Facts Support the Laboratory Origin of the COVID Virus

PR Newswire March 30, 2021

Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market

GlobeNewswire March 22, 2021

Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway

GlobeNewswire March 11, 2021

Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

GlobeNewswire February 25, 2021

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021

GlobeNewswire February 10, 2021

Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen

GlobeNewswire February 3, 2021

Atossa Therapeutics' Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early

GlobeNewswire February 2, 2021

Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants

GlobeNewswire January 29, 2021

New Study By Dr. Steven Quay Concludes that SARS-CoV-2 Came from a Laboratory

PR Newswire January 29, 2021

Registration Is Now Open For Tribe Public's Webinar Event "The Important Role of COVID Therapeutics in a Post-Vaccine World" Featuring Atossa Therapeutics' CEO & CFO On February 2, 2021

GlobeNewswire January 27, 2021

Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021

GlobeNewswire January 25, 2021

COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan Metro System Line 2 by Physician-Scientist Dr. Steven Quay

PR Newswire January 8, 2021

Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market

GlobeNewswire January 6, 2021

Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market

GlobeNewswire December 17, 2020

Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering

GlobeNewswire December 8, 2020

Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2020

Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

GlobeNewswire November 10, 2020

New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus Pandemic

Canada NewsWire October 28, 2020